Auf dem Weg zum Closed-Loop – Ziel und Realität

Zusammenfassung

Eine vollständig automatisierte Insulindosierung ist der Wunschtraum von Behandlern und Patienten mit Typ-1-Diabetes. Schon jetzt können sensorunterstützte Insulinpumpen reduzierend in die Insulinzufuhr eingreifen. Ziel von Forschungsarbeiten ist es, in das Zusammenspiel aus Pumpe und Sensor einen Algorithmus zu integrieren, der die automatische Abgabe des Insulins im Sinne eines vollständigen Regelkreislaufs (Closed-Loop) reguliert.

Abstract

An old dream of patients with type 1 diabetes and medical teams alike is a fully automated insulin therapy. Available sensor-augmented insulin-pumps are able to intervene in insulin therapy by reducing the dose. Aim of several studies is to add an algorithm to the interaction of pump and sensor, so that insulin doses can be regulated fully automatically. Totally closed loop systems are currently not yet available for outpatient use. Hybrid closed loop systems have been approved in the US. They can improve the metabolic status of patients with type 1 diabetes. Risks are similar to sensor-augmented insulin-pump therapy. Patients’ detailed education will continue to be essential for success.

Schlüsselwörter

CGM - CSII - Glukosesensor - Closed Loop - Hybrid-closed Loop - SuP

Key words

CGM - CSII - glucose sensor - closed loop - hybrid-closed loop - SAP

• Literatur

• 1 Siegmund T. Kolassa R. Thomas A. Sensorunterstützte Therapie (SuT) und sensorunterstützte Pumpentherapie (SuP). Bremen: UNI-MED; 2011
• 2 Mastrototaro JJ. The MiniMed Continuous Glucose Monitoring System. Diabetes Tech and Ther 2000; 2: S13-S18
• 3 Wentholt IM. Hart AA. Hoekstra JB. et al. Relationship between interstitial and blood glucose in type 1 diabetes patients: delay and the push-pull phenomenon revisited. Diabetes Technol Ther 2007; 9: 169-175
• 4 Heinemann L. Freckmann G. CGM Versus FGM; or, Continuous Glucose Monitoring Is Not Flash Glucose Monitoring. J Diabetes Sci Technol 2015; 9: 947-950
• 5 Gehr B. et al. SPECTRUM – Schulungs- und Behandlungsprogramm zur kontinuierlichen Glukosemessung (CGM) für Menschen mit Typ-1-Diabetes. Mainz: Kirchheim; 2016
• 6 Deutscher Gesundheitsbericht Diabetes 2017. Mainz: Kirchheim Verlag; 2016
• 7 Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Richtlinie Methoden vertragsärztliche Versorgung: Kontinuierliche interstitielle Glukosemessung mit Real-Time-Messgeräten (rtCGM) zur Therapiesteuerung bei Patientinnen und Patienten mit insulinpflichtigem Diabetes mellitus.. BAnz AT 06.09.2016 B3
• 8 Danne T. Kordonouri O. Holder M. et al. Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy. Diabetes Technol Ther 2011; 13: 1129-1134
• 9 Bergenstal RM. Klonoff DC. Garg SK. et al. ASPIRE In-Home Study Group. Threshold-basedinsulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013; 369: 224-232
• 10 Danne T. Tsioli C. Kordonouri O. et al. The PILGRIM Study: In Silico Modeling of a Predictive Low Glucos eManagement System and Feasibility in Youth with Type 1 Diabetes During Exercise. Diabetes Technol Ther 2014; 16: 338-347
• 11 Choudhary P. Olsen BS. Conget I. et al. Hypoglycemia Prevention and User Acceptance of an Insulin Pump System with Predictive Low Glucose Management. Diabetes Technol Ther 2016; 18: 288-291
• 12 Biester T. Danne T. Kordonouri O. et al. Hypoglyceamia prevention in children with Type 1 Diabetes by using Smartguard algorithm in Sensor-augmented Pump Therapy. Diabetes Technol Ther 2016; 18: P207
• 13 Kropff J. DeVries JH. Continuous Glucose Monitoring, Future Products, and Update on Worldwide Artificial Pancreas Projects. Diabetes Technol Ther 2016; 18: S253-S263
• 14 Phillip M. Battelino T. Atlas E. et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med 2013; 368: 824-833
• 15 Nimri R. Muller I. Atlas E. et al. Night glucose control with MD-Logic artificial pancreas in home setting: a single blind, randomized crossover trial-interim analysis. Ped Diab 2014; 15: 91-99
• 16 Thabit H. Tauschmann M. Allen JM. et al. APCam Consortium; AP@home Consortium. Home use of an artificial beta cell in type 1 diabetes. N Engl J Med 2015; 373: 2129-2140
• 17 Ruan Y. Thabit H. Leelarathna L. et al. AP@home Consortium. Variability of Insulin Requirements Over 12 Weeks of Closed-Loop Insulin Delivery in Adults With Type 1 Diabetes. Diab Care 2016; 39: 830-832
• 18 Dovc K. Macedoni M. Bratina N. et al. Closed-loop glucose control in young people with type 1 diabetes during and after unannounced physical activity: a randomised controlled crossover trial. Diabetologia 2017; 60 (11) 2157-2167
• 19 Weinzimer SA. Steil GM. Swan KL. et al. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diab Care 2008; 31: 934-939
• 20 Russell SJ. Hillard MA. Balliro C. et al. Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial. Lancet Diabetes Endocrinol 2016; 4: 233-243
• 21 Medtronic Company Announcement. Medtronic Receives FDA Approval for World's First Hybrid Closed Loop System for People with Type 1 Diabetes. September 28. 2016
• 22 Bergenstal RM. Garg S. Weinzimer SA. et al. Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes. JAMA 2016; 316: 1407-1408